Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers

Abstract

Mutations in Kirsten rat-sarcoma (KRAS) are well appreciated to be major drivers of human cancers through dysregulation of multiple growth and survival pathways. Similar to many other non-kinase oncogenes and tumor suppressors, efforts to directly target KRAS pharmaceutically have not yet materialized. As a result, there is broad interest in an alternative… (More)
DOI: 10.1111/cas.12383

4 Figures and Tables

Topics

Statistics

01020201520162017
Citations per Year

Citation Velocity: 5

Averaging 5 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.
  • Presentations referencing similar topics